Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "observations"

251 News Found

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review
Drug Approval | July 31, 2022

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing


Dr. Reddy's Laboratories updates on PAI of formulations facility
Drug Approval | July 08, 2022

Dr. Reddy's Laboratories updates on PAI of formulations facility

The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.


Cipla updates on US FDA product-specific pre-approval inspection
News | July 06, 2022

Cipla updates on US FDA product-specific pre-approval inspection

The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at Indore plant.


Glenmark Pharmaceuticals to address USFDA’s observation
News | June 23, 2022

Glenmark Pharmaceuticals to address USFDA’s observation

U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi


Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape
interviews | May 23, 2022

My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape

Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com


HPRA completes audit of Biocon Biologics New mAbs drug substance facility
Biotech | May 04, 2022

HPRA completes audit of Biocon Biologics New mAbs drug substance facility

The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency


Dr Vijay Shetty creates an alternative to x-ray examination
News | April 28, 2022

Dr Vijay Shetty creates an alternative to x-ray examination

The procedure, named 'Shetty Test' after its creator, could change the way suspected fractures are treated


Granules Pharmaceuticals clears USFDA audit
News | March 15, 2022

Granules Pharmaceuticals clears USFDA audit

This is the sixth successful USFDA audit for this facility


Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting
interviews | March 13, 2022

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements